The use and cost of diabetes in public drug plans

Transcription

1 PMPRB presentation in 2016 CAHSPR Conference The use and cost of diabetes in public drug plans Gary Warwick, Senior Economic Analyst, NPDUIS, PMPRB May 10, 2016

2 Supporting Health-Care Decision Making in Canada Purpose: to provide policy makers and public drug plan managers with critical analyses of price, utilization and cost trends, so that Canada's health care system has more comprehensive and accurate information on how prescription drugs are being on sources of cost pressures. Research initiative established in 2001 by F/P/T Ministers of Health A partnership between the PMPRB and the Canadian Institute for Health Information (CIHI) The NPDUIS Advisory Committee advises the PMPRB and provides expert oversight and guidance for the analytical reporting of the initiative Representation: BC, AB, SK, MB, ON, NB, NS, PEI, NL, YK, NIHB & HC, CIHI and CADTH CIHI NPDUIS Database houses pan-canadian prescription claims-level data from publicly financed drug benefit programs in Canada PMPRB NPDUIS uses a board array of data source to respond to the diverse analytical needs of its stakeholders. 2

3 3

4 4 The use and cost of diabetes in public drug plans Issue The cost of diabetes treatment has been rapidly increasing in Canada in recent years, spurred on by increasing prevalence rates and the access to increasingly expensive drugs. Objective To analyse these issues from the perspective of Canadian public drug plans, and provide insight into the actual use of the newer and higher-cost diabetes drugs and their associated cost pressures. Data sources and methods NPDUIS Database, Canadian Institute for Health Information. MIDAS Database, Retail Sector, Manufacturer Ex-factory Sales, IMS AG. All Rights Reserved. Methods Disclaimer Limitation Public plans reported: BC, AB, SK, MB, ON, NB, NS, PEI, NFL and NIHB Focus: 2014/15 Although based in part on data obtained from CIHI or provided under license by the IMS, the statements, findings, conclusions, views and opinions expressed in this report are exclusively those of the PMPRB and are not attributable to either data supplier. The results presented do not reflect pricing negotiated through confidential Product Listing Agreements.

5 Diabetes drug costs growing faster than the prevalence of the disease GROWTH IN DIABETES PREVALENCE AMONG NATIONAL POPULATION AND PUBLIC PLAN BENEFICIARIES, VS. GROWTH IN PUBLIC PLAN DIABETES COSTS National diabetes statistics, NPDUIS Public drug plans* Fiscal to Stats Can CANSIM

6 Diabetes account for a sizable and growing segment of the pharmaceutical market Trends are more pronounced in public plans 6 MIDAS Database, Retail Sector, Manufacturer Ex-factory Sales, IMS AG. All Rights Reserved.

7 Rapid growth in diabetes drug costs outpaced overall growth in public plans 7

8 Diabetes in public drug plans: more patients, more prescriptions, more high-cost drugs 8

9 In some public plans, diabetes drugs cost have been growing faster than drug use GROWTH IN DIABETES RELATED BENEFICIARIES, CLAIMS AND DRUG COSTS NPDUIS Public drug plans* Fiscal to

10 Diabetes treatment costs have been on the rise in recent years 10.

11 Newer high-cost long-acting insulins and DPP-4s have been the main cost drivers 11

12 Many diabetes patients use a combination therapy, with insulin and oral agents 12

13 Key Findings Treatment cost of diabetes has been on the rise, with diabetes accounting for a growing share of the cost: Due to the increased use and the use of higher-cost drugs; The use of insulin and emerging DPP-4s is an important cost driver; Although the use of the DPP-4s is relatively small, the impact on costs are high due to their relatively high treatment cost; A sizable share of insulin users were also using DPP-4s. 13

14 National Prescription drug Utilization Information System T H A N K Y O U Patented medicine prices review board Gary Warwick Gary.Warwick@pmprb-cepmb.gc.ca